CYP1A2 and early-onset autosomal dominant Alzheimer disease: In neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, an increase in tryptamine levels, stimulation of AHR, along with concomitant inhibition of the enzymes CYP1A1, CYP1B1 and CYP1A2, and inhibition of MAO could improve neurotransmitter balance and reduce neuroinflammation, potentially slowing disease progression.